BASEL (dpa-AFX) - Roche may in future market its eye medicine Vabysmo in a third indication in the EU. The EU Commission followed the recommendation of the Committee for Medicinal Products for Human Use (CHMP) a month ago and gave the green light for the treatment of retinal vein occlusion (RVO), as Roche announced on Tuesday.

Vabysmo is already approved in more than 95 countries worldwide. It can be used to treat neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). In several countries, such as the USA and Japan, it is also already approved for patients with retinal vein occlusion. Vabysmo and is a competitor product to Bayer's Eylea./hr/uh/AWP/mis